Open AccessIntegrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic
Author(s) -
Holly Hartman,
Yilun Sun,
Theresa P. Devasia,
Elizabeth C. Chase,
Neil Jairath,
Robert T. Dess,
Will Jackson,
Emily Morris,
Pin Li,
Kimberly A. Hochstedler,
Madeline R. Abbott,
Kelley M. Kidwell,
Vonn Walter,
Ming Wang,
Xi Wang,
Nicholas G. Zaorsky,
Matthew J. Schipper,
Daniel E. Spratt
Publication year - 2020
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2020.5403
Subject(s) - medicine , pandemic , cancer , survival analysis , comorbidity , covid-19 , stage (stratigraphy) , disease , intensive care medicine , infectious disease (medical specialty) , biology , paleontology
Cancer treatment delay has been reported to variably impact cancer-specific survival and coronavirus disease 2019 (COVID-19)-specific mortality during the severe acute respiratory syndrome coronavirus 2 pandemic. During the pandemic, treatment delay is being recommended in a nonquantitative, nonobjective, and nonpersonalized manner, and this approach may be associated with suboptimal outcomes. Quantitative integration of cancer mortality estimates and data on the consequences of treatment delay is needed to aid treatment decisions and improve patient outcomes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom